The State of the Art of Pediatric Multiple Sclerosis.
| Title: | The State of the Art of Pediatric Multiple Sclerosis. |
|---|---|
| Authors: | Teleanu RI; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; Niculescu AG; Research Institute of the University of Bucharest-ICUB, University of Bucharest, 050657 Bucharest, Romania.; Department of Science and Engineering of Oxide Materials and Nanomaterials, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Vladacenco OA; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; Roza E; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; Perjoc RS; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; Teleanu DM; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Department of Neurosurgery, Emergency University Hospital, 050098 Bucharest, Romania. |
| Source: | International journal of molecular sciences [Int J Mol Sci] 2023 May 04; Vol. 24 (9). Date of Electronic Publication: 2023 May 04. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| MeSH Terms: | Multiple Sclerosis*/therapy ; Multiple Sclerosis*/drug therapy ; Neurodegenerative Diseases*/diagnosis; Adolescent ; Adult ; Humans ; Child ; Young Adult ; Central Nervous System ; Risk Factors ; Diagnosis, Differential |
| Abstract: | Multiple sclerosis (MS) represents a chronic immune-mediated neurodegenerative disease of the central nervous system that generally debuts around the age of 20-30 years. Still, in recent years, MS has been increasingly recognized among the pediatric population, being characterized by several peculiar features compared to adult-onset disease. Unfortunately, the etiology and disease mechanisms are poorly understood, rendering the already limited MS treatment options with uncertain efficacy and safety in pediatric patients. Thus, this review aims to shed some light on the progress in MS therapeutic strategies specifically addressed to children and adolescents. In this regard, the present paper briefly discusses the etiology, risk factors, comorbidities, and diagnosis possibilities for pediatric-onset MS (POMS), further moving to a detailed presentation of current treatment strategies, recent clinical trials, and emerging alternatives. Particularly, promising care solutions are indicated, including new treatment formulations, stem cell therapies, and cognitive training methods. |
| References: | Children (Basel). 2019 Jun 03;6(6):. (PMID: 31163654); Mult Scler J Exp Transl Clin. 2017 Nov 21;3(4):2055217317743097. (PMID: 29348926); Dev Neuropsychol. 2018;43(6):524-534. (PMID: 29911891); Children (Basel). 2019 Feb 04;6(2):. (PMID: 30720736); Biosens Bioelectron. 2015 Jun 15;68:660-667. (PMID: 25660510); Brain Sci. 2021 May 14;11(5):. (PMID: 34069276); Eur J Neurol. 2019 Jan;26(1):27-40. (PMID: 30300457); Ther Adv Neurol Disord. 2022 Oct 8;15:17562864221127476. (PMID: 36225970); Mult Scler Relat Disord. 2020 Sep;44:102260. (PMID: 32540746); Neurology. 2019 Sep 24;93(13):e1299-e1311. (PMID: 31471502); Neurology. 2002 Feb 26;58(4):658-60. (PMID: 11865153); Qual Health Res. 2019 Apr;29(5):645-657. (PMID: 29911511); Am J Med. 2020 Dec;133(12):1380-1390.e2. (PMID: 32682869); Front Neurol. 2019 Apr 05;10:338. (PMID: 31024432); BMC Neurol. 2018 Jun 8;18(1):82. (PMID: 29884144); Curr Treat Options Neurol. 2019 Sep 27;21(10):50. (PMID: 31560095); Neurology. 2008 Mar 25;70(13 Pt 2):1107-12. (PMID: 18272867); Arch Neurol. 2007 Aug;64(8):1157-61. (PMID: 17698706); JMIR Mhealth Uhealth. 2015 Aug 31;3(3):e85. (PMID: 26323749); Neurology. 2016 Aug 30;87(9 Suppl 2):S12-9. (PMID: 27572856); Front Immunol. 2017 May 18;8:531. (PMID: 28572801); Am Psychol. 2017 May-Jun;72(4):326-338. (PMID: 28481580); Front Mol Neurosci. 2022 Jan 03;14:801882. (PMID: 35046772); Pediatr Res. 2020 Jan;87(2):345-352. (PMID: 31641280); BMC Neurol. 2018 Mar 9;18(1):27. (PMID: 29523094); Front Neurol. 2020 Aug 21;11:851. (PMID: 32973654); Front Neurol. 2018 Oct 23;9:888. (PMID: 30405519); Front Neurol. 2020 Sep 08;11:996. (PMID: 33013658); Eur J Paediatr Neurol. 2022 Jan;36:130-136. (PMID: 34959110); Children (Basel). 2022 Nov 05;9(11):. (PMID: 36360426); Neuropsychology. 2011 May;25(3):319-32. (PMID: 21534686); Pediatr Neurol. 2018 Jun;83:19-24. (PMID: 29681490); Mult Scler Relat Disord. 2022 Oct;66:104008. (PMID: 35863128); Mult Scler. 2013 Sep;19(10):1323-9. (PMID: 23549432); Lancet Neurol. 2018 Feb;17(2):162-173. (PMID: 29275977); Neurology. 2021 May 4;96(18):e2313-e2322. (PMID: 34038379); Neurology. 2015 Jul 14;85(2):177-89. (PMID: 26092914); Pediatr Radiol. 2020 May;50(6):776-792. (PMID: 31925460); Lancet. 2017 Dec 2;390(10111):2481-2489. (PMID: 29029896); Neurology. 2012 Jan 17;78(3):194-201. (PMID: 22218275); Expert Opin Biol Ther. 2019 Aug;19(8):829-843. (PMID: 31027436); Lancet Neurol. 2019 Sep;18(9):845-856. (PMID: 31285147); Arch Neurol. 2009 Sep;66(9):1144-50. (PMID: 19752305); Brain Sci. 2020 Jan 17;10(1):. (PMID: 31963428); Int J Mol Sci. 2019 Sep 04;20(18):. (PMID: 31487788); Brain Sci. 2021 Jan 09;11(1):. (PMID: 33435314); J Pers Med. 2022 Oct 05;12(10):. (PMID: 36294795); Curr Treat Options Neurol. 2015 Mar;17(3):336. (PMID: 25680425); Trends Mol Med. 2020 Mar;26(3):296-310. (PMID: 31862243); Neurology. 2006 Dec 12;67(11):2063-5. (PMID: 17159123); Neurol Neuroimmunol Neuroinflamm. 2018 Jun 07;5(4):e466. (PMID: 29892607); Arch Neurol. 2007 Jan;64(1):72-5. (PMID: 17210811); Mult Scler. 2006 Jun;12(3):294-301. (PMID: 16764342); Lancet Neurol. 2020 Dec;19(12):988-997. (PMID: 33222767); Adv Pediatr. 2019 Aug;66:209-229. (PMID: 31230695); Mult Scler. 2021 Feb;27(2):259-267. (PMID: 32975459); Cancers (Basel). 2023 Apr 06;15(7):. (PMID: 37046846); Contemp Clin Trials. 2021 Jan;100:106219. (PMID: 33212293); Neurology. 2014 Apr 15;82(15):1314-21. (PMID: 24647027); Lancet Neurol. 2017 Feb;16(2):104-106. (PMID: 28102146); Lancet. 2018 Mar 17;391(10125):1000. (PMID: 29565004); Int J Mol Sci. 2022 May 25;23(11):. (PMID: 35682631); Expert Rev Neurother. 2022 Aug;22(8):681-693. (PMID: 35881416); Croat Med J. 2019 Apr 30;60(2):87-98. (PMID: 31044580); Mult Scler J Exp Transl Clin. 2021 Dec 01;7(4):20552173211059048. (PMID: 34868629); Eur Radiol. 2018 Mar;28(3):1140-1148. (PMID: 28986640); Neuroepidemiology. 2016;47(2):103-108. (PMID: 27723651); Obes Res Clin Pract. 2014 Sep-Oct;8(5):e435-47. (PMID: 25263833); Front Mol Neurosci. 2018 May 16;11:164. (PMID: 29867354); Neurology. 2013 Feb 5;80(6):548-52. (PMID: 23365063); Neurol Ther. 2016 Dec;5(2):131-143. (PMID: 27640189); J Pers Med. 2022 Nov 03;12(11):. (PMID: 36579555); Clin Pharmacol Ther. 2022 Feb;111(2):373-381. (PMID: 33792920); Ann Neurol. 2023 Feb;93(2):285-296. (PMID: 36093738); Mult Scler. 2016 Apr;22(5):628-40. (PMID: 26286701); J Neurol. 2019 Sep;266(9):2157-2163. (PMID: 31129709); NPJ Digit Med. 2020 Jul 31;3:101. (PMID: 32821856); Mult Scler Relat Disord. 2019 Nov;36:101368. (PMID: 31557681); Mult Scler. 2013 Sep;19(10):1261-7. (PMID: 23572237); Mult Scler. 2016 Jun;22(7):878-83. (PMID: 26362895); P T. 2012 Mar;37(3):175-84. (PMID: 22605909); Radiology. 2005 Jul;236(1):254-60. (PMID: 15987979); Int J Mol Sci. 2018 Nov 20;19(11):. (PMID: 30463275); Mult Scler. 2019 Jan;25(1):72-80. (PMID: 28933245); Eur J Paediatr Neurol. 2019 Nov;23(6):783-791. (PMID: 31540711); Neurol Neuroimmunol Neuroinflamm. 2020 May 13;7(4):. (PMID: 32404429); Neuroreport. 2011 Dec 21;22(18):1005-9. (PMID: 22045260); Lancet Neurol. 2021 Sep;20(9):762-772. (PMID: 34418402); Neurorehabil Neural Repair. 2019 Sep;33(9):695-706. (PMID: 31328637); Pediatr Neurol. 2019 Aug;97:56-63. (PMID: 31060768); Neuromodulation. 2018 Jun;21(4):383-389. (PMID: 28225155); JAMA. 2021 Feb 23;325(8):765-779. (PMID: 33620411); Neurology. 2014 Dec 2;83(23):2140-6. (PMID: 25378667); Front Neurol. 2021 Mar 15;12:652811. (PMID: 33790852); Mult Scler. 2021 Feb;27(2):165-166. (PMID: 33476254); Mult Scler. 2020 May;26(6):659-667. (PMID: 30912689); J Child Neurol. 2019 Sep;34(10):612-620. (PMID: 31234708); J Neurol. 2021 Nov;268(11):4066-4077. (PMID: 32719975); Curr Opin Neurol. 2022 Jun 1;35(3):262-270. (PMID: 35674067); JAMA. 2004 Apr 21;291(15):1875-9. (PMID: 15100207); Qual Life Res. 2017 Sep;26(9):2333-2349. (PMID: 28393317); Lancet Neurol. 2007 Sep;6(9):773-81. (PMID: 17689148); Lancet Neurol. 2021 Sep;20(9):709-720. (PMID: 34418398); Ann Neurol. 2006 Mar;59(3):499-503. (PMID: 16502434); JAMA Neurol. 2020 Dec 1;77(12):1572-1575. (PMID: 32777005); J Neurol. 2022 Mar;269(3):1316-1334. (PMID: 34382120); Mult Scler. 2011 Sep;17(9):1122-9. (PMID: 21543552) |
| Contributed Indexing: | Keywords: clinical trials; emerging therapeutic strategies; multiple sclerosis treatment; pediatric multiple sclerosis |
| Entry Date(s): | Date Created: 20230513 Date Completed: 20230515 Latest Revision: 20230515 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10179691 |
| DOI: | 10.3390/ijms24098251 |
| PMID: | 37175954 |
| Database: | MEDLINE |
Journal Article; Review